Pegasys Growth Strategy Will Focus On HIV/HCV Co-Infection And Hepatitis B
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche's pegylated interferon product has captured 52% of total Rxs. APRICOT study in HIV/HCV co-infection shows Pegasys/Copegus (ribavirin) combo therapy yields 40% sustained virologic response.
You may also be interested in...
Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review
Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).